Bofanglutide is a new biweekly GLP-1 drug for type 2 diabetes and weight loss management The drug showed greater HbA1c reduction than weekly semaglutide in a 24-week trial in China Patients on bofanglutide experienced significant weight loss and improved cholesterol levels